BioWorld

July 8, 2004

View Archived Issues

Acusphere Licenses AI-700 EU Rights to Nycomed For $70M

Retaining U.S. marketing rights for itself, Acusphere Inc. signed a deal with Nycomed Group for the European rights to its lead product, AI-700. (BioWorld Today) Read More

Celera Partners Antigens With Abbott In Oncology Agreement

Read More

Cardiome Starts Third Phase III Of RSD1235 In Atrial Fibrillation

Read More

AmpliMed Setting Amplimexon Clinical Development Strategy

Read More

Other News To Note

Read More